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Purpose or Objective  
We have treated 250 patients at our center from May 
2015 to September 2017 for breast cancer with Axxent 
(Xoft Inc.) intraoperative radiotherapy (IORT) following 
the inclusion parameters of the TARGIT study, in this 
work we compare the doses in the skin of the first 150 
patients treated with the 50 kVp source with the skin 
doses they would have received using the Mammosite kit 
using an Ir192 source. 
Material and Methods  
To the 250 patients treated in our center after removing 
the tumor, the appropriate balloon size is chosen to 
cover the tumor area with a dose of 20 Gy on the balloon 
surface, the sizes used range from 30-65 cm3, after 
which it is verified that the distance to skin from the 3 
closest points of the balloon is less than 10 mm and then 
the treatment is carried out with an average duration of 
10.3 minutes being the volumes of 30 and 35 cm3 the 
most used due to the inclusion criteria of the procedure. 
Treatment plans are previously performed in a 
Brachyvision treatment planning system (TPS) (Varian 
Inc.) for each of the possible volumes. In turn, another 
plan is calculated with the Mammosite applicator and 
Ir192 source, from which the skin dose of each control 
point is estimated, compared to our results. We present 
also the cases of acute dermatitis seen for these first 150 
patients in a time less than 6 months after the surgical 
act and irradiation. 
Results  
The differences in maximum skin dose for both types of 
treatment are 8.1 ± 1.2 Gy for the case of Mammosite 
and 5.7 ± 1.5 Gy for patients treated with electronic 
source, due to the difference in the depht dose 
percentage of both types of treatment (Image 1). This, in 
turn, explains the very few cases of acute dermatitis at 6 
months (8 cases of grade 2 and 2 cases of grade 3) (Image 
2) with no recurrence to date.We also show the mean and 
maximum doses (expressed as percentage of prescribed 
dose) for the left lung and heart in cases of left breast 
tumor for the volumes of 30 and 35 cm3, which are the 
most common volumes in our hospital (70% of cases): 
 
LEFT LUNG (Left Breast tratment) AXXENT MAMMOSITE 
Maximun Dose (%PD) 20.4% 29.9% 
Mean Dose (%PD) 1.0% 3.9% 
HEART (Left Breast tratment) AXXENT MAMMOSITE 
Maximun Dose (%PD) 4.1% 10.4% 





It is concluded that the IORT treatments performed with 
the Axxent equipment with electronic source are a good 
alternative to those performed with Ir192 and our 250 
patients treated to date to the good results presented by 
other centers are joined.In addition to the low skin 
toxicity, there is no recurrence in patients treated so far, 
which makes us very optimistic about the results. 
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Purpose or Objective  
To test the safety & efficacy of 0.5% hydrogen peroxide 
in 1% sodium hyaluronate gel (KORTUC) delivered by 
intratumoural injection twice-weekly during external 
beam radiotherapy (RT) to patients with locally 
advanced/recurrent breast cancer with or without 
associated distant metastases. 
 
